Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis.
Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis.
复制标题
体重指数，前列腺特异性死亡率和生化复发：系统评价和荟萃分析。
DOI：
10.1158/1940-6207.capr-10-0229
复制
发表时间：
2011-04
期刊：
影响因子：
--
通讯作者：
Ma J
中科院分区：
文献类型：
--
作者：
Cao Y;Ma J
越来越多的证据表明，肥胖(以体重指数(BMI)衡量)与前列腺癌特有的死亡率有关，其对生化复发的影响也不确定。系统检索截至2010年1月5日的MEDLINE、EMBASE和检索到的研究文献。我们使用随机效应荟萃分析来评估前列腺癌特异性死亡率和生化复发与BMI增加5 kg/m2相关的相对风险(RR)。在对1,263,483名最初没有癌症的男性进行的6项基于人群的队列研究中，有6,817人死于前列腺癌；体重指数每增加5公斤/平方米与前列腺癌死亡风险增加15%(RR 1.15，95%CI 1.06-1.25，p<；0.01)相关。在对18,203名前列腺癌死亡患者的6项诊断后生存研究中，体重指数每增加5公斤/平方米与前列腺癌相关死亡率增加20%(相对危险度1.20，95%可信区间0.99-1.46，p=0.06)。在对26,479名前列腺癌患者进行初步治疗后的16项研究中，体重指数每增加5公斤/平方米与生化复发风险增加21%显著相关(相对危险度1.21，95%可信区间1.11-1.31 p<；0.01)。在前瞻性队列研究中，BMI升高与前列腺癌特异性死亡率和前列腺癌患者的生化复发风险相关。在确诊的患者中，它与前列腺癌特异性死亡率的相关性需要进一步评估。
Increasing evidence suggested obesity, measured by body-mass index (BMI), was associated with prostate cancer-specific mortality, and its impact on biochemical recurrence was also inconclusive. We systematically searched MEDLINE, EMBASE and bibliographies of retrieved studies up to Jan 5th, 2010. We used random-effects meta-analysis to assess the relative risks (RR) of prostate cancer-specific mortality and biochemical recurrence associated with a 5 kg/m2 increase in BMI. Among the 6 population-based cohort studies in 1,263,483 initially cancer-free men, 6,817 prostate cancer deaths occurred; a 5kg/m2 increase in BMI was associated with 15% (RR 1.15, 95%CI 1.06–1.25, p<0.01) higher risk of dying of prostate cancer. In the 6 post-diagnosis survival studies on 18,203 patients with 932 prostate cancer deaths, a 5kg/m2 increase in BMI was associated with 20% higher prostate cancer-specific mortality (RR 1.20, 95%CI 0.99–1.46, p=0.06). In the 16 studies which followed 26,479 prostate cancer patients after primary treatment, a 5kg/m2 increase in BMI was significantly associated with 21% increased risk of biochemical recurrence (RR 1.21, 95%CI 1.11–1.31 p<0.01). Elevated BMI is associated with risk of prostate cancer-specific mortality in prospective cohort studies and biochemical recurrence in prostate cancer patients. Its association with prostate cancer-specific mortality in diagnosed patients needs to be further evaluated.